Skip to content



About MDC002

MDC002 is a novel oral therapeutic being developed to treat patients with ME/CFS. It has further potential in diseases where chronic fatigue is associated with Fibromyalgia, Gulf War syndrome, Lyme disease, ANCA vasculitis, Marfan syndrome, and Ehlers-Danlos syndromes. MDC002 could also be effective in curing an undisclosed rare disease (not related to fatigue). MDC002 is ready for GLP toxicity and GLP safety pharmacology studies. It is an orally applicable small molecule stimulating the sodium-potassium pump Na+/K+-ATPase and the mitochondrial sodium-calcium exchanger NCLX in skeletal muscle.